Setmelanotide (IMCIVREE) and Melanotan II: Same Peptide Family, Different Regulatory Worlds

There is a hormone in your body called alpha-MSH. Your pituitary gland makes small amounts of it every day. It tells your skin cells to make more pigment. It also tells your brain to feel less hungry. And, in men, it can trigger sustained erections.

In the 1990s and 2000s, chemists made two different synthetic peptides that copy the effects of alpha-MSH. One is called setmelanotide. It is sold today under the brand name IMCIVREE by a company called Rhythm Pharmaceuticals (NASDAQ: RYTM). It has full FDA approval. On August 4, 2026, Rhythm reported that more than 400 patients had started IMCIVREE in a new indication in the first six weeks after approval.

The other is called melanotan II. It has no FDA approval anywhere in the world. It is sold gray-market as a tanning drug, mostly to people trying to get darker skin without spending time in the sun. Australia's drug regulator has banned it. The UK regulator has warned against it. Doctors have reported serious side effects including new moles, painful erections that required emergency treatment, kidney problems, and (in one case) brain swelling. In February 2027, an FDA advisory panel will vote on whether US compounding pharmacies should be allowed to prepare it.

Both molecules copy alpha-MSH. Both do broadly similar things in the body. One is a real medicine. The other is a research chemical people inject at home. Why? That question is what this piece is really about, and the answer is a good window into how pharma works.

Alpha-MSH is short for alpha-melanocyte-stimulating hormone. It is a small peptide, made of just 13 amino acids. Amino acids are the building blocks of proteins; peptides are short chains of them.

Alpha-MSH does more than one thing. It attaches to five different receptors in the body, and each receptor triggers a different response. Think of a receptor as a lock. Alpha-MSH is a key that fits five different locks, each of which opens a different door.

Here are the five doors alpha-MSH opens:

• Melanocortin receptor 1 (MC1R) sits on skin cells called melanocytes. Opening this door tells the skin to make more melanin, the pigment that darkens skin.
• Melanocortin receptor 3 (MC3R) sits mostly in a part of the brain called the hypothalamus. Opening this door reduces hunger.
• Melanocortin receptor 4 (MC4R) also sits in the hypothalamus and other brain areas. Opening this door also reduces hunger, and does so more powerfully than MC3R. In some people, opening this door also produces sustained erections.
• Melanocortin receptor 5 (MC5R) sits in oil glands and other tissues. What opening this door does is less well understood.
• MC2R sits in the adrenal glands. This one is triggered mostly by a different hormone (ACTH) rather than alpha-MSH.

This is what makes alpha-MSH interesting to drug developers. If you could open only one specific door (say, MC4R for hunger), you might have a very useful appetite drug with minimal side effects. If you open all the doors at once, you get skin darkening, appetite loss, and erections all in one shot. The difference between a targeted drug and a scattershot chemical is the difference between opening one door and opening five.

Setmelanotide was designed to open one door mostly. It binds strongly to MC4R (the powerful hunger receptor) and much less strongly to the other four. That specificity is not perfect, but it is much better than the natural hormone.

Why MC4R? Because there is a group of patients who need exactly that door opened. Some people are born with genetic mutations that break parts of the MC4R signaling pathway in their brain. Their brain never gets a clear message to stop eating. They feel constantly hungry from a young age and become severely obese despite normal or even reduced eating for their body weight. The genes involved include POMC, PCSK1, and LEPR, plus a rare inherited condition called Bardet-Biedl Syndrome. There is also a group called acquired hypothalamic obesity, where a brain tumor (usually a rare childhood tumor called craniopharyngioma) or the surgery and radiation used to treat it damages the hypothalamus and disrupts appetite signaling.

Rhythm Pharmaceuticals ran clinical trials in these specific patient groups. In 2020, the FDA approved setmelanotide (as IMCIVREE) for the rare genetic obesity syndromes. In 2022, the approval extended to Bardet-Biedl Syndrome. And in June 2026, the FDA approved it for the acquired hypothalamic obesity indication based on a Phase 3 trial called TRANSCEND, whose full results were published in the New England Journal of Medicine on July 8, 2026.

The launch has been strong. Rhythm reported on the August 4, 2026 earnings call that more than 400 patients had started IMCIVREE in the new acquired hypothalamic obesity indication within the first six weeks. Q1 2026 IMCIVREE revenue reached $60.1 million, up 59% year over year, with growth continuing since.

Here is what makes setmelanotide a drug and not a research chemical:

• A company (Rhythm) took responsibility for developing it, funding trials, and supporting patients.
• A specific patient population was identified where the appetite-suppression effect was clearly medically useful.
• Randomized clinical trials proved it worked in those patients.
• The FDA reviewed the safety data and monitoring plan.
• A prescription-only distribution system means patients get the drug through a doctor who tracks their response and side effects.
• Pediatric use is approved starting at age 4, which means the FDA has data on how it affects children.

All of that is invisible in the vial. What you see is a peptide that reduces hunger. What you do not see is the machinery that made it a medicine.

Melanotan II was made in the 1990s at the University of Arizona. Chemists there were studying the melanocortin receptor system. They designed a synthetic peptide that copied alpha-MSH but was more stable and worked better than the natural hormone. It was originally intended as a research tool, and one of the ideas was that it might one day be a way to prevent skin cancer by making the skin darker without needing sun exposure.

That drug development story never happened. Melanotan II has never been submitted to the FDA for approval as a drug. It has never gone through Phase 3 trials. No company has committed to running the studies, supporting the monitoring, or standing behind the safety data.

What did happen: an entire online market grew up around it. Vendors sell melanotan II as a research chemical in vials, usually labeled 'not for human use,' at a price of roughly $20 to $50 per vial. Buyers reconstitute the powder at home with sterile water, load it into insulin syringes, and inject it under the skin. Most users are chasing skin darkening, sometimes for cosmetic tanning, sometimes with a vague idea that being tan protects against sun damage. Some are chasing the appetite suppression. Some are chasing the erection effect.

Unlike setmelanotide, melanotan II is not selective. It hits all five melanocortin receptors with roughly similar strength. Users are opening all the doors at once. That produces skin darkening (the goal for most users), but it also produces the side effects.

The reported side effects are not minor:

• New moles or existing moles darkening or changing shape. Some users have had biopsies. Dermatology case reports document a range of concerning skin changes. Whether melanotan II directly causes melanoma is not proven, but the biological plausibility is real, and Australia's regulator has cited two melanoma cases among 89 adverse events reported on the drug.
• Priapism, which is the medical term for a prolonged, painful erection that can require emergency treatment. This is more than an inconvenience: untreated priapism can cause permanent tissue damage.
• Nausea, vomiting, facial flushing, and yawning fits are common.
• Kidney problems, low sodium in the blood, and (in one case report) posterior reversible encephalopathy syndrome (a form of brain swelling) have been documented.

Regulators have taken note. Australia's Therapeutic Goods Administration bans possession without a research license. The UK's medicines regulator has issued warnings. The FDA has sent warning letters to online sellers who market it for human use. Individual EU countries have taken their own actions.

The February 2027 US PCAC review will ask whether melanotan II should be added to the Section 503A bulk drug substances list. If added, US compounding pharmacies could prepare it under prescription for medical use. That would not make it an FDA-approved drug for tanning. It would create a legal pathway for specific medical uses in specific patients. That is a real change, but a limited one. See the Melanotan II PCAC review piece for the full picture on that vote.

The setmelanotide/melanotan II split is a good lens on how the pharmaceutical industry actually works. A molecule does not become an approved drug just by existing or by having useful effects. It becomes an approved drug by going through a specific set of steps, each of which costs a lot of money and takes years.

Here is the machinery, in plain language:

Step 1: Someone has to take responsibility. A company (or, less often, an academic group with a grant) has to decide to develop the molecule. That means committing to spend money on trials, manufacturing, and safety monitoring. Without a sponsor, nothing happens. Rhythm Pharmaceuticals decided to develop setmelanotide. No company has decided to develop melanotan II.

Step 2: A specific medical problem gets defined. You cannot get a drug approved for 'general use.' The FDA approves drugs for specific conditions in specific patients. Setmelanotide is approved for rare genetic obesity syndromes and now acquired hypothalamic obesity. If Rhythm had tried to get it approved for 'appetite suppression in anyone who wants to lose weight,' the trials would have been enormous and the risk-benefit calculation would have been different. Picking a specific patient group where the treatment matters most makes the trials smaller, faster, and more likely to succeed.

Step 3: Clinical trials happen in three main phases. Phase 1 tests safety and dosing in small numbers of healthy volunteers or patients. Phase 2 tests whether the drug seems to work in the target patients. Phase 3 tests it against placebo or existing standard of care in a much larger group, usually hundreds to thousands of patients, and produces the data the FDA uses to decide on approval. The full process typically takes 7 to 10 years and costs hundreds of millions to over a billion dollars. Setmelanotide went through all three phases in the rare-disease patient groups. Melanotan II did not.

Step 4: The FDA reviews the entire package. The agency looks at safety data, efficacy data, manufacturing quality, labeling, and post-approval monitoring commitments. Approval comes with specific instructions: what dose, for what condition, in what patients, with what monitoring. Rhythm has to comply with all of those. Melanotan II vendors do not, because there is no approval and no framework.

Step 5: Approved drugs get a distribution and monitoring channel. IMCIVREE reaches patients through prescribing physicians who track their response, adjust dosing, and watch for side effects. Rhythm has a specialty pharmacy network, a patient support program, and formal reporting requirements for adverse events. If something goes wrong, the FDA knows. Nothing like that exists for melanotan II. If a user has priapism at 2 AM, no company gets notified. The event might make it into a case report years later if a curious clinician writes it up. Otherwise it just happens quietly.

That is the machinery. It is expensive, slow, and imperfect. It is also the reason approved drugs work more reliably and cause fewer surprises than research chemicals people inject at home.

The setmelanotide/melanotan II story is not unique. Many of the drugs approved every year have gray-market twins: molecules with similar effects that are sold outside the approval system to people who want the effect without waiting for the approval. Sometimes the gray-market versions come first (like melanotan II, which was made in the 1990s while setmelanotide's approval came in 2020). Sometimes they come later, when someone reverse-engineers an approved drug and sells it cheaper without the safety infrastructure.

A few patterns are worth naming.

Rare-disease indications are often the entry point for a mechanism. Rhythm chose to develop setmelanotide for POMC, PCSK1, and LEPR deficiency — genetic conditions that affect maybe a few thousand people in the US. That is a very small market. But it is a market where the medical need is undeniable, the trial size can be manageable, and the FDA is more willing to approve a drug that carries some risk because the alternative (severe uncontrolled obesity from childhood) is worse. Once approved for a rare disease, the same drug can then be studied in broader indications. This is a common pharma playbook: enter through a niche, expand from there. AbbVie's Humira started in rheumatoid arthritis and eventually expanded to nine indications. Setmelanotide has expanded from three rare genetic syndromes to Bardet-Biedl Syndrome to acquired hypothalamic obesity, and future expansions in adjacent conditions are being studied.

Gray markets thrive where medical need meets slow approval processes. Melanotan II grew popular because people wanted to be tan, dermatologists were warning them against sun exposure, and no legal alternative existed. Similar gray markets exist around growth hormone (used off-label for anti-aging), various compounded weight-loss peptides (during and after the GLP-1 shortages), and many others. The demand comes first; the approval catches up, or does not.

Not every good idea gets developed into a drug. Melanotan II might, in principle, have become a real medicine for a specific indication. But no company decided to spend the $500 million to a billion dollars needed to run the trials. The reasons include: uncertain market size, safety concerns that would require careful monitoring, and other higher-priority projects competing for capital. Drug development is not a purely scientific process. It is also a business process. Molecules that do not fit a business case sit on the shelf, and other companies (or gray-market vendors) sometimes pick them up in ways that were not part of the original plan.

Peptide drugs specifically are in a moment. The GLP-1 class (Wegovy, Ozempic, Zepbound, Mounjaro) has made obesity peptides one of the most valuable drug categories in the world. Amylin analogs, GIP agonists, glucagon agonists, and now melanocortin agonists like setmelanotide are all riding that wave. Peptide manufacturing has scaled up. Regulatory pathways for peptides are being clarified (the July 2026 PCAC vote on BPC-157, KPV, and others is part of that clarification). New peptide drugs are entering the market faster than at any point in the last thirty years. The setmelanotide launch story is one example of what that pipeline looks like when it works.

Selectivity is a big part of the modern peptide story. Setmelanotide is more selective than melanotan II. Tirzepatide's dual GIP/GLP-1 action is more targeted than a simple GLP-1 alone. Peptide radioligand therapies (like Novartis's Pluvicto and the ITM 177Lu-edotreotide currently working through FDA review) are more targeted still, delivering radiation only to tumor cells that express a specific receptor. The trend across the industry is toward more selective peptides that produce more of the wanted effects and less of the unwanted ones. That trend takes chemistry effort and long trials, but it produces drugs that hold up under scrutiny.

For a general reader, the story here reaches beyond two peptides. It is about how to think about the difference between a drug and a chemical that acts like a drug.

If you see a peptide product advertised online or in a wellness clinic, a few questions are worth asking:

Is it FDA-approved for what it is being sold for? Setmelanotide is FDA-approved for specific rare-disease indications; if you have one of those conditions, IMCIVREE is a real medicine and your endocrinologist can prescribe it. Melanotan II is not approved for anything; if it is being sold to you for tanning or appetite suppression, you are being sold a research chemical, not a drug.

Who takes responsibility if something goes wrong? For IMCIVREE, that is Rhythm Pharmaceuticals plus the prescribing doctor plus the pharmacy plus the FDA's post-marketing safety monitoring system. For gray-market melanotan II, the answer is nobody. If you have a bad reaction, the online vendor does not have a medical team to help, and the FDA cannot track the event to a specific product batch.

What is the monitoring plan? Approved drugs come with dose recommendations, contraindication lists, and safety monitoring schedules. Gray-market chemicals come with forum posts. Those are different things.

Is the price too low to be real? Setmelanotide costs roughly $10,000 to $20,000 per month at the list price (much of which is usually covered by insurance for the approved indications). A vial of gray-market melanotan II costs $20 to $50. That difference reflects the difference in what you are actually buying: a supported medical product versus a raw research chemical.

Setmelanotide and melanotan II are related peptides. Both copy the natural hormone alpha-MSH. Both do broadly similar things in the body. One is an FDA-approved rare-disease medicine that recorded 400 patient starts in six weeks after a new indication was approved in June 2026. The other is a gray-market research chemical that regulators around the world have warned against.

The difference is not in the chemistry alone, though the receptor selectivity does matter. The difference is in the machinery around the molecule: a sponsor, defined patient groups, clinical trials, FDA review, prescribing physicians, monitoring systems, and pediatric safety data. Setmelanotide has all of that. Melanotan II has none of it.

For patients with the specific conditions setmelanotide treats, IMCIVREE is a real option worth discussing with an endocrinologist. For people considering melanotan II for cosmetic tanning or general appetite suppression, the reported side effects (mole changes, priapism, kidney reports, nausea and vomiting) and the total absence of safety monitoring are reasons to think carefully.

The broader lesson: pharmaceutical approval is more than paperwork. It is a system that produces reliable medicines by requiring specific evidence, distributed accountability, and post-market monitoring. When people bypass that system to buy chemicals directly, they save money and time, but they also give up everything the system provides. Whether that trade-off is worth it depends on the individual case. Understanding what you are actually trading is the first step to making a good decision.